HC Wainwright Forecasts iBio’s Q1 Earnings (NASDAQ:IBIO)

iBio, Inc. (NASDAQ:IBIO) – Equities research analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for shares of iBio in a research note issued to investors on Thursday, September 17th. HC Wainwright analyst A. Ghosh anticipates that the company will post earnings of ($0.05) per share for the quarter. HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for iBio’s current full-year earnings is ($0.39) per share. HC Wainwright also issued estimates for iBio’s Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.10) EPS, FY2027 earnings at ($0.30) EPS, Q1 2028 earnings at ($0.09) EPS, Q2 2028 earnings at ($0.12) EPS, Q3 2028 earnings at ($0.16) EPS, Q4 2028 earnings at ($0.25) EPS, FY2028 earnings at ($0.62) EPS, FY2029 earnings at ($0.51) EPS and FY2030 earnings at ($0.57) EPS.

iBio (NASDAQ:IBIO) last issued its quarterly earnings data on Friday, August 28th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.03.

Other equities analysts have also recently issued reports about the company. B. Riley Financial initiated coverage on iBio in a research note on Friday, June 5th. They set a “buy” rating and a $6.00 price objective on the stock. Chardan Capital reiterated a “buy” rating and issued a $5.00 target price on shares of iBio in a research note on Thursday, July 2nd. Wall Street Zen downgraded shares of iBio from a “hold” rating to a “sell” rating in a report on Sunday, September 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of iBio in a research report on Wednesday, June 24th. Finally, Raymond James Financial started coverage on shares of iBio in a report on Monday, June 8th. They set an “outperform” rating and a $5.00 price target on the stock. Three investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $5.29.

iBio Stock Up 5.6%

Shares of NASDAQ:IBIO opened at $1.33 on Monday. The business’s 50 day moving average is $1.36 and its 200 day moving average is $1.69. iBio has a 12-month low of $0.77 and a 12-month high of $3.82. The stock has a market cap of $85.53 million, a price-to-earnings ratio of -3.91 and a beta of 1.29.

Hedge Funds Weigh In On iBio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IBIO. Headlands Technologies LLC boosted its position in iBio by 333.0% during the second quarter. Headlands Technologies LLC now owns 47,413 shares of the company’s stock valued at $83,000 after buying an additional 36,463 shares during the period. Jefferies Financial Group Inc. purchased a new stake in iBio during the 4th quarter valued at about $309,000. Monashee Investment Management LLC purchased a new stake in iBio during the 4th quarter valued at about $530,000. Bank of America Corp DE grew its position in iBio by 150.8% during the 1st quarter. Bank of America Corp DE now owns 290,413 shares of the company’s stock worth $552,000 after acquiring an additional 174,620 shares during the last quarter. Finally, Noesis Capital Mangement Corp grew its position in iBio by 38.9% during the 1st quarter. Noesis Capital Mangement Corp now owns 311,500 shares of the company’s stock worth $592,000 after acquiring an additional 87,300 shares during the last quarter. 7.90% of the stock is currently owned by hedge funds and other institutional investors.

About iBio

iBio, Inc is a biotechnology company focused on discovering and developing next-generation antibody therapeutics. The company uses artificial intelligence, machine learning and computational biology to identify antibody candidates and optimize their properties for potential use in cancer, autoimmune, inflammatory and fibrotic diseases.

iBio’s technology platform is based in part on the antibody-discovery capabilities obtained through its acquisition of RubrYc Therapeutics. The platform is designed to support target selection, antibody generation and optimization, with an emphasis on identifying antibodies that bind specific disease-related epitopes.